SCHEMBL7360600

SCHEMBL7360600

CC(=O)N[C@H](C(=O)N[C@H](C(=O)O)C(C)C)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.42
ALDH1A1 P00352 4/20 0.42
MME P08473 1/20 0.41
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
PLA2G2A P14555 1/20 0.40
PLA2G5 P39877 1/20 0.40
POLB P06746 1/20 0.39
FPR2 P25090 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
NFKB1 P19838 1/20 0.38
PTGS2 P35354 1/20 0.38
THPO P40225 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7766358 1.00 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1MMELMNAGAA
SCHEMBL193513 0.91 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1MMELMNAGAA
SCHEMBL1203937 0.91 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1MMELMNAGAA
SCHEMBL132349 0.91 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1MMELMNAGAA
SCHEMBL30953203 0.90 MME (0.41) SMN1; SMN2ALDH1A1MMELMNAGAA
SCHEMBL8058978 0.89 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1MMELMNAGAA
Ammonia Solution, Strong SCHEMBL10483779 0.89 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1MMELMNAGAA
SCHEMBL7105559 0.89 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1LMNAGAAHPGD
Ammonia Solution, Strong SCHEMBL10483782 0.89 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1MMELMNAGAA
SCHEMBL25412479 0.85 MME (0.43) SMN1; SMN2ALDH1A1MMELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595299-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2009-09-29 US disclosed
US-7595299-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2009-09-29 US disclosed
US-7169760-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2007-01-30 US disclosed
US-7169760-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2007-01-30 US disclosed
EP-0876329-B1 PROCESS FOR THE PRODUCTION OF N-ACETYL-D,L-ALPHA-AMINOCARBOXYLIC ACIDS DEGUSSA (DE) 2001-07-18 EP disclosed
EP-0874801-B1 PROCESS FOR OBTAINING OPTICALLY ACTIVE L-ALPHA-AMINOCARBOXYLIC ACIDS FROM CORRESPONDING RACEMIC D,L-ALPHA-AMINOCARBOXYLIC ACIDS DEGUSSA (DE) 2001-06-13 EP disclosed
US-6114163-A ACETYLATING RACEMIC MIXTURE, NEUTRALIZING SOLUTION, DEACETYLING USING STEREOSPECIFIC ACYLASE TO PRODUCE L-STEREOISOMERS, SEPARATING OUT WANTED PRODUCT, ADJUSTING SOLUTION, RACEMIZING MIXTURE, AND DEACETYLATING AGAIN DEGUSSA AKTIENGESELLSCHAFT (DE) 2000-09-05 US disclosed
EP-0415981-A4 RETROVIRAL PROTEASE INHIBITORS 1991-10-09 EP disclosed
EP-0415981-A1 RETROVIRAL PROTEASE INHIBITORS ABBOTT LABORATORIES (US) 1991-03-13 EP disclosed
EP-0342541-A2 Retroviral protease inhibitors ABBOTT LABORATORIES (US) 1989-11-23 EP disclosed
WO-1989010752-A1 RETROVIRAL PROTEASE INHIBITORS ABBOTT LABORATORIES (US) 1989-11-16 WO disclosed